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The molecular clock is a master controller of circadian cellular processes that affect growth, metabolic ho-
meostasis, and behavior. A report in Science by Zhang et al. (2015) redefines our understanding of how
Rev-erba acts as an internal feedback inhibitor that modulates activity of the core clock while simultaneously
regulating tissue-specific metabolic processes.The molecular clock is composed of
a transcriptional-translational feedback
loop. Heterodimers of the transcription
factors BMAL1 (brain and muscle ARNT-
like protein 1) and CLOCK (circadian loco-
motor output cycles kaput) or NPAS2
(neuronal PAS domain containing protein
2) stimulate gene expression of period
(Per1,2,3) and cryptochrome (Cry1,2).
PER/CRY heterodimers then inhibit the
activity of BMAL1–CLOCK/NPAS2 lead-
ing to a self-sustaining oscillation in gene
expression. The nuclear receptors (NRs)
Rev-erb (Rev-erba, Rev-erbb) and retinoic
acid receptor-likeorphan receptor (RORa,
RORb, and RORg) directly regulate Bmal1
gene expression. Rev-erbs and RORs
recognize and compete for the same
‘‘response elements’’ in the genome,
including the one found in the Bmal1 pro-
moter. Rev-erbs are transcriptional re-
pressors, while RORs are transcriptional
activators. Rev-erbs and RORs are ex-
pressed in a circadian fashion antiphase
to one another, contributing to the circa-
dian pattern of clock gene expression.
Physiologically relevant ligands for both
of these NR classes have been identified,
implying that they also function as sensors
of nutrient flux and/or metabolic state
(Kojetin and Burris, 2014). Rev-erbs serve
as receptors for heme (Raghuram et al.,
2007; Yin et al., 2007), whereas RORa
and RORg display high affinity for various
oxysterols (Jin et al., 2010; Kallen et al.,
2002; Wang et al., 2010).
Beyond the clock, Rev-erbs and RORs
regulate expression of genes involved in
immune function, behavior, muscle meta-
bolism, and lipid and glucose homeo-
stasis. A recent publication suggests
that Rev-erb may employ distinct regula-
torymechanismswith regard to regulationof clock genes versus other tissue-
specific non-clock genes (Zhang et al.,
2015). Unexpectedly, comparing Rev-
erba cistromes in the brain (20,000 bind-
ing sites), liver (9,000), and white adi-
pose tissue (8,500) revealed remarkably
little overlap in receptor binding sites.
Only 183 sites were common to all
three tissues, typically near clock genes
including Bmal1, Cry1, Npas2, Nr1d1,
and E4pb4, containing classically defined
Rev-erb DNA response elements (ROREs
and RevDR2s). However, the tissue-spe-
cific sites did not typically contain ROREs
or RevDR2s. In fact, these sites were
enriched for response elements for other
transcription factors specific for each
tissue examined. For example, Rev-erb
binding sites in the liver were heavily en-
riched for HNF4A and HNF6 binding sites,
while in the fat CEBP response elements
were enriched. In the liver, RORs (RORa
and RORg) competed for common Rev-
erb binding sites in clock genes, but not
in Rev-erba tissue-selective binding sites.
The authors hypothesized that Rev-erb
might be regulating many genes indepen-
dent of its DNA binding domain. This was
tested using a Rev-erba knockout mouse
that expresses a mutated Rev-erba pro-
tein lacking a DNA binding domain
(DBDm mice). In mice only expressing
the DBDm Rev-erb, Rev-erb binding sites
were dramatically reduced at the com-
mon sites (clock sites); however, the bind-
ing signal at the tissue-selective sites was
maintained. This demonstrates that there
are two mechanisms by which Rev-erb
can regulate genes—DBD dependent
and DBD independent. Remarkably, the
DBD-independent mechanism may be
the predominant mechanism, perhaps
involving tethering to other factors.Cell Metabolism 2Liver DBD-independent Rev-erb sites
were enriched for HNF6 DNA response
elements, and the group demonstrated
that these sites were indeed bound by
HNF6. Furthermore, simultaneous bind-
ing of Rev-erba and HNF6 at DBD-inde-
pendent sites was observed, but not
DBD-dependent sites. Physiological
importance of the DBD-independent sites
was supported by comparison of gene
expression and metabolic phenotype of
Rev-erba DBDm and Rev-erba knockout
mice. Rev-erb-regulated genes involved
in hepatic lipid metabolism are predomi-
nantly regulated by the DBD-independent
mechanism, since they were de-re-
pressed in Rev-erba knockout mice,
which also exhibited hepatic steatosis,
but were expressed normally in Rev-erba
DBDm mice that were not steatotic.
Several NRs have been shown to exert
transcriptional regulatory effects via indi-
rect tethering. However, the finding that
the vast majority of the Rev-erb binding
sites do not require the DBD was clearly
not expected. Segregating function in
terms of DBD-dependent versus -inde-
pendent sites is also important. The
DBD-dependent sites focus primarily
on clock regulation, while DBD-indepen-
dent sites focus on tissue-selective
functions. This separates circadian re-
gulation that is found in all cell types,
where competition with RORs is an
important component of the pathway,
from the maintenance of circadian os-
cillations in expression of tissue-selective
Rev-erb target genes. One role of the core
clock is to maintain high-amplitude circa-
dian oscillations in Rev-erb expression
(Rev-erba is one of the common DBD-
dependent genes itself). DBD-indepen-
dent genes may therefore be considered2, August 4, 2015 ª2015 Elsevier Inc. 197
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‘‘tethering’’ mechanism also allows for
‘‘modular’’ flexibility between cell types
expressing different anchor proteins. The
RORs display a similar profile to Rev-
erbs in terms of a very distinctive function
regulating the clock, but additional spe-
cific roles in the regulation of develop-
ment, immune function, etc., exist. It is
possible that RORs operate with a similar
segregation of function, but future work
will be required to address this possibility.
We have been intrigued by the distinct
activities of drugs targeting these two
classes of NRs. If the predominant mech-
anism of action of these receptors were
via direct DNA binding via recognition of
a RORE/RevDR2, then targeting them
should have similar outcomes with Rev-
erb activators acting similar to ROR
inhibitors. However, this has not been
observed in many cases. For example,
Rev-erb agonists (Banerjee et al., 2014),
but not RORa/g inverse agonists (T.P.B.,
unpublished data), are anxiolytic and
induce wakefulness. The research by
Zhang et al. (2015) suggests that most
genes targeted by Rev-erb are regulated
independently of the DBD and are thus198 Cell Metabolism 22, August 4, 2015 ª201also regulated independently of competi-
tion from RORs. Considerable differences
between the actions of these drugs are
therefore expected. Zhang et al. (2015)
also suggest that, due to the distinct reg-
ulatory mechanisms, it may be possible to
pharmacologically target DBD-indepen-
dent Rev-erb pathways while sparing the
DBD-dependent pathways, providing for
a drug avoiding general effects on the
circadian clock. This would not be a
trivial undertaking given that we typically
target Rev-erb’s ligand binding domain.
It is also unclear whether one could
modulate DBP-dependent and -indepen-
dent pathways independently with our
current understanding of NR drug devel-
opment. Finally, it is fascinating to specu-
late that we could pharmacologically
target specific tissues using synthetic
Rev-erb ligands designed to modulate
tissue- specific Rev-erb/tethered partner
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Two articles in this issue (Intlekofer et al., 2015; Oldham et al., 2015) show a newmetabolic pathway regulated
by hypoxia, but independently of HIF1 or HIF2. L-2-hydroxyglutarate, produced in hypoxia by malate dehy-
drogenases and LDHA, is a potent inhibitor of KDM4C, and through redox stress reduces glycolysis.A key step in the Krebs cycle is the
conversion of isocitrate to 2-oxoglutarate,
and thereafter to succinate. Mutations
in isocitrate dehydogenases IDH1 and
IDH2 result in conversion of 2-oxogluta-
rate (also known as alpha-ketoglutarate)
to D(R)-2-hydroxyglutarate, an oncome-
tabolite that can inhibit enzymes that use2-oxoglutarate as a cofactor with oxygen
(Losman and Kaelin, 2013). These are
dioxygenases, which include TET1 and
TET2, enzymes that modify 5-methylcyto-
sine residues in DNA and hence gene
transcription (Figure 1).
Two papers published in this issue
(Oldham et al., 2015; Intlekofer et al.,2015) describe another metabolite, a
normal product of 2-oxoglutarate meta-
bolism, the L(S)-2-hydroxyglutarate iso-
mer. Thismetabolite was previously noted
as a product of IDH in hypoxia, but its
role was unknown. These papers pre-
sent evidence of increased production
of L-2-hydroxyglutarate in hypoxia. The
